Pfizer Covid-19 vaccine sales hit $3.5bn in first quarter
CEO Albert Bourla sees ‘durable demand for Covid-19 vaccine
04 May 2021 - 19:22
Pfizer laid out a plan to turn its Covid-19 vaccine into a long-term business, clinching supply agreements that will yield $26bn in sales in 2021 while expanding the shot to children, as its Covid-19 vaccine drew $3.5bn in sales in the first quarter.
The drugmaker’s revenue forecast was an increase from $15bn, a reflection of strong demand worldwide for a return to normality. Pfizer said it now expects to deliver 1.6-billion doses in 2021 under contracts signed by mid-April, with half the profits going to partner BioNTech...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.